The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a 2-Year Phase II SBIR Grant Totaling $1,919,714.00
Doylestown, PA. June 24, 2013– FCCDC is pleased to announce that it has been awarded a 2-year Phase II SBIR grant (R44 CA156781-02) totaling $1,919,714 entitled “Riluzole Prodrugs for Melanoma and ALS”.